A Czech scientist has contributed to understanding the function of the thymus—the training center of the immune system. T ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the ...

BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...

Even for a newly minted Nobel laureate, downtime is hard to find. | Even for a newly minted Nobel laureate, downtime is hard to find. Just a few weeks after winning the 2025 Nobel Prize in Physiology ...

Selected by a Distinguished Jury of Global Biopharma Leaders for Dren Bio’s Outstanding Innovation, Impact, and Scientific Excellence – SAN CARLOS, ...

At ACR 2025, early data of CTA313, a universal CD19/BCMA CAR-T therapy, demonstrate safety and strong responses in refractory ...

CoV-2, has led to the first approval of mRNA vaccines in humans. By producing the full-length SARS-CoV-2 Spike protein, they ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces clinical data for CT0596, an allogeneic BCMA-targeting CAR-T ...

The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack ...

The company utilizes cell-targeted lipid nanoparticles (ctLNP) to deliver small interfering RNA (siRNA) to T cells, aiming to reprogram them and reduce the production of autoreactive T cells. Average ...

Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDTCompany ...

Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body? There are instances where killer T cells—which are meant to precisely remove virus-infected ...